Ionis Pharmaceuticals 2024 Performance ReportFinancial statementsIonis Pharmaceuticals reported a 2024 revenue decline of 11%, with a $475 million operating loss. The report highlights product sales from Spinraza, Wainua, Qalsody, and others, alongside its cash reserves and 2025 guidance.